Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05926570
Other study ID # 36264PR295/8/23
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date August 5, 2023
Est. completion date January 22, 2024

Study information

Verified date January 2024
Source Tanta University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Chronic kidney disease (CKD) is defined as either renal damage and/ or a glomerular filtration rate (GFR) below 60 mL/min/1.73 m2 for more than 3 months. End stage renal disease (ESRD) is defined as GFR below 15 mL/min/1.73 m2. Secondary hyperparathyroidism (SHPT) is an insidious disease that develops early in the course of CKD and increase in severity as the GFR deteriorates. High serum levels of intact parathyroid hormone (iPTH) are known to cause high turnover bone disease, i.e. osteitis fibrosa and have also been reported to increase the mortality risk in patients undergoing hemodialysis (HD). Standard therapy for SHPT includes dietary calcium supplementation, active vitamin D, and phosphate binders; however, these are often insufficient to allow patients to achieve their serum parathyroid hormone (PTH), calcium and calcium-phosphorus product (Ca × P) targets. Recent preclinical studies have demonstrated that treatment with calcimimetics that increase the sensitivity of the calcium-sensing receptor (CaR) to calcium can reverse the alterations in CaR and vitamin D receptor expression and parathyroid cell proliferation that are associated with SHPT. Calcimimetics such as cinacalect are positive allosteric modulators of the calcium-sensing receptor that increase its sensitivity by lowering the threshold for activation by extracellular calcium ions. The calcimimetic cinacalcet mainly increases the sensitivity of the CaR to extracellular Ca, thus inhibiting the release of PTH, although, as recently shown, it also decreases PTH synthesis. Growth hormone (GH) indirectly promotes the growth of child by stimulating the production of insulin like growth factor (IGF-1), many children with renal disease have normal or elevated level of GH in their blood otherwise the levels of IGF-1 are low because the approximately 98% of IGF-1 is always bound to one of binding proteins (BP) inside the liver, so this accumulated protein will reduce the function of IGF-1. Using cinacalcet in controlling hyperparathyroidism may reduce growth problems in children with ESRD with regular hemodialysis.


Description:

This interventional study will be conducted at Nephrology Unit Pediatric Department Tanta University Hospital (TUH) for a period of 6 months starting from August 2023. Study duration 6 months from August 2023 to February 2024. Place of the study: Nephrology Unit at TUH. Study sample: This study will be conducted on 35 children and adolescents with end stage renal disease on regular hemodialysis for three to four times weekly at our nephrology Unit at TUH during the period of the study. Inclusion criteria: Pediatric patients with end stage renal disease aged from 8 to 18 years on regular hemodialysis. Exclusion criteria: - Controlled hyperparathyroidism- PTH <300 pg/ml. - Children < 8y. - Previous parathyroidectomy - children on growth hormone therapy All patients included in the study will be subjected to: 1. History taking including duration of dialysis and regular drugs that are taken. 2. Clinical examination including anthropometric measurements and blood pressure estimation. All measurements will be taken in the dialysis free day 3. Investigations A- Routine investigations: including - Complete blood picture - Serum albumin Serum creatinine, blood urea level● - Serum CRP B- Specific investigations: including - Serum insulin growth factor-1 using ELIZA kits. - Serum parathyroid hormone. - Serum calcium. - Serum phosphorus. - Serum alkaline phosphatase. Sample collection: Seven millilitres of venous blood will be collected under complete aseptic precautions at 8 AM and before dialysis session before and after one month of cinacalcet treatment. Five millilitres will be put in a plain test tube without anticoagulant, and the remaining two millilitres will be put in a test tube with ethylene diamine tetra-acetic acid (EDTA) as an anticoagulant, to be used for performing complete blood count. After clotting, the samples will be centrifuged at 1500 xg for 15 minutes. Part of the separated serum will be used to perform serum creatinine, urea, albumin and blood urea nitrogen (BUN). The rest of the serum will be separated and will be used for the subsequent assay of IGF-1 serum level by enzyme-linked immunosorbent assay (ELISA). Hemolysed samples will be discarded. Repeated thawing and freezing will be avoided. 4. treatment received: All children will receive cinacalcet in a dose of 30 mg/day taken with food for 3 months, in addition to their supportive treatment including erythropoietin injection, oral calcium, one alpha, folic acid and antihypertensive drugs to hypertensive patients.


Recruitment information / eligibility

Status Completed
Enrollment 35
Est. completion date January 22, 2024
Est. primary completion date January 22, 2024
Accepts healthy volunteers No
Gender All
Age group 8 Years to 18 Years
Eligibility Inclusion Criteria: - Pediatric patients with end stage renal disease aged from 5 to 18 years on regular hemodialysis. Exclusion Criteria: - Controlled hyperparathyroidism- PTH <300 pg/ml. - Children < 8y. - Previous parathyroidectomy - children on growth hormone therapy

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Cinacalcet
calcimimetic

Locations

Country Name City State
Egypt Sara Mabrouk Mohamed Elghoul Tanta

Sponsors (1)

Lead Sponsor Collaborator
Tanta University

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary correlation between PTH and serum IGF-1 correlation between serum levels of parathyroid hormone and serum insulin like growth factor-1 in pediatric patients with ESRD on regular hemodialysis 3 months
Secondary Cinacalcet effect on level of IGF-1 cinacalcet will be given in a dose of 39mg/day with food for 3 months 3 months
See also
  Status Clinical Trial Phase
Completed NCT04235894 - An Observer Rating Scale of Facial Expression Can Predict Dreaming in Propofol Anesthesia
Completed NCT04166890 - Comparison of the Efficacy and Safety of Two Homologous Active Principles for Local Dental Anesthesia Phase 4
Completed NCT03265613 - Safety and Efficacy of Expanded Allogeneic AD-MSCs in Patients With Moderate to Severe Psoriasis Phase 1/Phase 2
Recruiting NCT04037774 - Comparision of Different Doses of Dexmedetomidine With Low Dose Bupivacaine in Selective Spinal Anesthesia. Phase 4
Recruiting NCT05113420 - The Efficacy and Safety of Different Phlebotonic Drugs in Children With Venous Malformations
Completed NCT03801629 - Neuroimmune Effects of Opioid Administration Phase 1
Completed NCT04052776 - Acute Effects of Pharmacological Neuromodulation on Leg Motor Activity in Patients With SCI Treated With EES Phase 1
Completed NCT04037085 - Ketamine to Improve Recovery After Cesarean Delivery - Part 1 Phase 2
Completed NCT05050071 - Evaluation of Antibacterial Effect of Allium Sativum, Calcium Hydroxide and Their Combination in Infected Mature Teeth Phase 2/Phase 3
Completed NCT03305666 - Trial of Injected Liposomal Bupivacaine vs Bupivacaine Infusion After Surgical Stabilization of Rib Fractures Phase 4
Completed NCT06238154 - Flurbiprofen Tablet vs Spray In Oral Soft Tissue Wounds Phase 4
Not yet recruiting NCT04392427 - New Antiviral Drugs for Treatment of COVID-19 Phase 3
Recruiting NCT05300152 - Pulpotomy Medications in Primary Teeth N/A
Recruiting NCT04594889 - Comparison of Sirolimus vs Paclitaxel Drug Eluting Balloon for Below-the-knee Angioplasty in Critical Limb Ischemia N/A
Not yet recruiting NCT05018936 - Efficacy and Safety of Hetrombopag in Non-severe Aplastic Anemia Phase 2/Phase 3
Completed NCT04245774 - Comparing the Effects of Levobupivacaine and Bupivacaine in Saddle Spinal Anesthesia Phase 4
Completed NCT04449536 - Cysteine-lowering Treatment With Mesna Phase 1
Recruiting NCT05975255 - Dose Finding Study for Remimazolam in Children Phase 2
Active, not recruiting NCT04254731 - Effects of Switching From Racemic Methadone to R-methadone on QTc Intervals Phase 4
Completed NCT03635684 - Evaluation of Efficacy and Safety of Subcutaneous Acetaminophen Phase 2